vs
Mirion Technologies, Inc.（MIR）とONTO INNOVATION INC.（ONTO）の財務データ比較。上の社名をクリックして会社を切り替えられます
Mirion Technologies, Inc.の直近四半期売上が大きい（$277.4M vs $218.2M、ONTO INNOVATION INC.の約1.3倍）。ONTO INNOVATION INC.の純利益率が高く（12.9% vs 6.2%、差は6.7%）。Mirion Technologies, Inc.の前年同期比売上増加率が高い（9.1% vs -13.5%）。ONTO INNOVATION INC.の直近四半期フリーキャッシュフローが多い（$82.0M vs $63.2M）。過去8四半期でMirion Technologies, Inc.の売上複合成長率が高い（20.0% vs 2.6%）
ミリオンテクノロジーズ社は放射線検出、モニタリング、安全ソリューションのグローバルプロバイダーです。主力製品は個人線量測定システム、放射線画像装置、放射線リスク管理ソフトウェアで、原子力発電、医療、防衛、産業分野を中心に世界各国の顧客にサービスを提供しています。
Onto Innovation Inc.はアメリカの半導体関連企業で、2019年にRudolph Technologies社とNanometrics社の合併により誕生しました。マイクロエレクトロニクス製造業界向けに製造プロセスやプロセス制御に必要な機器、ソフトウェアソリューションを提供しています。
MIR vs ONTO — 直接比較
損益計算書 — Q4 2025 vs Q3 2025
| 指標 | | |
|---|---|---|
| 売上 | $277.4M | $218.2M |
| 純利益 | $17.3M | $28.2M |
| 粗利率 | 48.8% | 50.7% |
| 営業利益率 | 9.2% | 10.9% |
| 純利益率 | 6.2% | 12.9% |
| 売上前年比 | 9.1% | -13.5% |
| 純利益前年比 | 15.3% | -46.8% |
| EPS（希薄化後） | $0.07 | $0.57 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $277.4M | — | ||
| Q3 25 | $223.1M | $218.2M | ||
| Q2 25 | $222.9M | $253.6M | ||
| Q1 25 | $202.0M | $266.6M | ||
| Q4 24 | $254.3M | $263.9M | ||
| Q3 24 | $206.8M | $252.2M | ||
| Q2 24 | $207.1M | $242.3M | ||
| Q1 24 | $192.6M | $228.8M |
| Q4 25 | $17.3M | — | ||
| Q3 25 | $2.9M | $28.2M | ||
| Q2 25 | $8.3M | $33.9M | ||
| Q1 25 | $300.0K | $64.1M | ||
| Q4 24 | $15.0M | $48.8M | ||
| Q3 24 | $-13.6M | $53.1M | ||
| Q2 24 | $-11.7M | $52.9M | ||
| Q1 24 | $-25.8M | $46.9M |
| Q4 25 | 48.8% | — | ||
| Q3 25 | 46.8% | 50.7% | ||
| Q2 25 | 46.0% | 48.2% | ||
| Q1 25 | 47.6% | 53.7% | ||
| Q4 24 | 48.1% | 50.2% | ||
| Q3 24 | 44.9% | 54.1% | ||
| Q2 24 | 47.0% | 52.9% | ||
| Q1 24 | 45.2% | 51.7% |
| Q4 25 | 9.2% | — | ||
| Q3 25 | 3.3% | 10.9% | ||
| Q2 25 | 4.4% | 12.7% | ||
| Q1 25 | 4.3% | 23.7% | ||
| Q4 24 | 11.4% | 16.1% | ||
| Q3 24 | -0.8% | 21.0% | ||
| Q2 24 | 1.1% | 20.2% | ||
| Q1 24 | -2.5% | 18.7% |
| Q4 25 | 6.2% | — | ||
| Q3 25 | 1.3% | 12.9% | ||
| Q2 25 | 3.7% | 13.4% | ||
| Q1 25 | 0.1% | 24.0% | ||
| Q4 24 | 5.9% | 18.5% | ||
| Q3 24 | -6.6% | 21.0% | ||
| Q2 24 | -5.6% | 21.9% | ||
| Q1 24 | -13.4% | 20.5% |
| Q4 25 | $0.07 | — | ||
| Q3 25 | $0.01 | $0.57 | ||
| Q2 25 | $0.03 | $0.69 | ||
| Q1 25 | $0.00 | $1.30 | ||
| Q4 24 | $0.08 | $0.98 | ||
| Q3 24 | $-0.07 | $1.07 | ||
| Q2 24 | $-0.06 | $1.07 | ||
| Q1 24 | $-0.13 | $0.94 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $412.3M | $603.1M |
| 総負債低いほど良い | — | — |
| 株主資本純資産 | $1.9B | $2.0B |
| 総資産 | $3.6B | $2.2B |
| 負債/資本比率低いほどレバレッジが低い | — | — |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $412.3M | — | ||
| Q3 25 | $933.2M | $603.1M | ||
| Q2 25 | $262.6M | $217.5M | ||
| Q1 25 | $185.8M | $203.7M | ||
| Q4 24 | $175.2M | $212.9M | ||
| Q3 24 | $133.3M | $188.7M | ||
| Q2 24 | $122.2M | $172.6M | ||
| Q1 24 | $120.2M | $190.9M |
| Q4 25 | — | — | ||
| Q3 25 | $444.8M | — | ||
| Q2 25 | $444.9M | — | ||
| Q1 25 | $686.6M | — | ||
| Q4 24 | $686.4M | — | ||
| Q3 24 | $685.1M | — | ||
| Q2 24 | $684.1M | — | ||
| Q1 24 | $685.5M | — |
| Q4 25 | $1.9B | — | ||
| Q3 25 | $1.8B | $2.0B | ||
| Q2 25 | $1.5B | $2.0B | ||
| Q1 25 | $1.5B | $1.9B | ||
| Q4 24 | $1.5B | $1.9B | ||
| Q3 24 | $1.5B | $1.9B | ||
| Q2 24 | $1.5B | $1.8B | ||
| Q1 24 | $1.5B | $1.8B |
| Q4 25 | $3.6B | — | ||
| Q3 25 | $3.5B | $2.2B | ||
| Q2 25 | $2.7B | $2.1B | ||
| Q1 25 | $2.6B | $2.1B | ||
| Q4 24 | $2.6B | $2.1B | ||
| Q3 24 | $2.7B | $2.1B | ||
| Q2 24 | $2.6B | $2.0B | ||
| Q1 24 | $2.6B | $2.0B |
| Q4 25 | — | — | ||
| Q3 25 | 0.24× | — | ||
| Q2 25 | 0.30× | — | ||
| Q1 25 | 0.46× | — | ||
| Q4 24 | 0.46× | — | ||
| Q3 24 | 0.45× | — | ||
| Q2 24 | 0.45× | — | ||
| Q1 24 | 0.47× | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $73.0M | $83.4M |
| フリーキャッシュフロー営業CF - 設備投資 | $63.2M | $82.0M |
| FCFマージンFCF / 売上 | 22.8% | 37.6% |
| 設備投資強度設備投資 / 売上 | 3.5% | 0.6% |
| キャッシュ転換率営業CF / 純利益 | 4.22× | 2.95× |
| 直近12ヶ月FCF直近4四半期 | $106.9M | $261.3M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $73.0M | — | ||
| Q3 25 | $22.3M | $83.4M | ||
| Q2 25 | $12.4M | $57.9M | ||
| Q1 25 | $35.6M | $92.0M | ||
| Q4 24 | $60.8M | $56.0M | ||
| Q3 24 | $17.1M | $67.2M | ||
| Q2 24 | $15.2M | $65.3M | ||
| Q1 24 | $6.0M | $57.1M |
| Q4 25 | $63.2M | — | ||
| Q3 25 | $13.0M | $82.0M | ||
| Q2 25 | $3.6M | $44.2M | ||
| Q1 25 | $27.1M | $83.7M | ||
| Q4 24 | $49.1M | $51.4M | ||
| Q3 24 | $3.9M | $59.2M | ||
| Q2 24 | $4.1M | $53.0M | ||
| Q1 24 | $-6.8M | $50.2M |
| Q4 25 | 22.8% | — | ||
| Q3 25 | 5.8% | 37.6% | ||
| Q2 25 | 1.6% | 17.4% | ||
| Q1 25 | 13.4% | 31.4% | ||
| Q4 24 | 19.3% | 19.5% | ||
| Q3 24 | 1.9% | 23.5% | ||
| Q2 24 | 2.0% | 21.9% | ||
| Q1 24 | -3.5% | 21.9% |
| Q4 25 | 3.5% | — | ||
| Q3 25 | 4.2% | 0.6% | ||
| Q2 25 | 3.9% | 5.4% | ||
| Q1 25 | 4.2% | 3.1% | ||
| Q4 24 | 4.6% | 1.8% | ||
| Q3 24 | 6.4% | 3.2% | ||
| Q2 24 | 5.4% | 5.1% | ||
| Q1 24 | 6.6% | 3.0% |
| Q4 25 | 4.22× | — | ||
| Q3 25 | 7.69× | 2.95× | ||
| Q2 25 | 1.49× | 1.71× | ||
| Q1 25 | 118.67× | 1.44× | ||
| Q4 24 | 4.05× | 1.15× | ||
| Q3 24 | — | 1.27× | ||
| Q2 24 | — | 1.23× | ||
| Q1 24 | — | 1.22× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
MIR
| Transferred Over Time | $96.6M | 35% |
| Services | $65.0M | 23% |
| Cancer Care | $61.8M | 22% |
| Labs And Research | $34.0M | 12% |
| Other Care | $20.7M | 7% |
ONTO
| Systems And Software Revenue | $173.8M | 80% |
| Parts Revenue | $23.9M | 11% |
| Service Revenue | $20.5M | 9% |
